Abbott Humira Marketing Will Challenge RA Competitors On Dosing, Efficacy
Executive Summary
Abbott will highlight Humira dosing convenience, efficacy and price to encourage switching of rheumatoid arthritis patients from Amgen/Wyeth's Enbrel or Johnson & Johnson's Remicade
You may also be interested in...
UCB Acquiring Celltech; Phase III TNF Inhibitor At Center Of $2.7 Bil. Deal
UCB is paying $2.7 bil. to lock up rights to Celltech's TNF inhibitor CDP-870
UCB Acquiring Celltech; Phase III TNF Inhibitor At Center Of $2.7 Bil. Deal
UCB is paying $2.7 bil. to lock up rights to Celltech's TNF inhibitor CDP-870
Abbott “Knolls” When To Quit: Large-Scale Mergers Not On Agenda, CEO Says
Abbott's acquisition of Knoll has given the company enough "critical mass" to meet its pharmaceutical growth goals, Abbott CEO Miles White indicated during an investor call Jan. 16